Mek-Nf-201- A Phase 2B Trial Of The Mek 1/2 Inhibitor (Meki) Pd-0325901 In Adult And Pediatric Patients With Neurofibromatosis Type 1 (Nf1)-Associated Inoperable Plexiform Neurofibromas (Pns) That Are Causing Significant Morbidity
Posted Date: Sep 11, 2020
- Investigator: Soma Sengupta
- Specialties:
- Type of Study: Drug
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). The primary endpoint of this study is to determine Complete or partial response rate compared to baseline.
Criteria:
To Be Eligible: Must Have Documented Nf1 Mutation Or A Diagnosis Of Neurofibromatosis Type 1 Unresectable Plexiform Neurofibroma Causing Significant Morbidity, Adequate Organ And Bone Marrow Function, No Other Malignancy Within 5 Years, Or Breast Cancer
Keywords:
Neurofibromas, Brain Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com